Antithrombotic therapy for ischaemic stroke patients with AF/RHD in west China daily practice

Neurological Research

Volumn 37, Issue 10, 2015, Pages 902-907

  Wang, Deren ^a   Liu, Junfeng ^a   Hao, Zilong ^a   Liu, Ming ^a   Tan, Ge ^a   Jiang, Xiaoqun ^a,b   Tao, Wendan ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU FIFTH PEOPLE S HOSPITAL   (China)

Author keywords

Antithrombotic therapy; Atrial fibrillation; Comparative research; Ischaemic stroke; Rheumatic heart disease

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RHEUMATIC HEART DISEASE; RISK ASSESSMENT; CHINA; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MIDDLE AGED; STROKE; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BRAIN ISCHEMIA; CHINA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84940204774     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132815Y.0000000071     Document Type: Article

References (30)

1. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362:1211–24.
2. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2:43–53.
3. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol. 2007;6:456–64.
4. Arboix A, Alio J. Acute cardioembolic cerebral infarction: answers to clinical questions. Curr Cardiol Rev. 2012;8:54–67.
5. Lin S, Wu B, Hao ZL, Kong FY, Tao WD, Wang DR, et al. Characteristics, treatment and outcome of ischemic stroke with atrial fibrillation in a Chinese hospital-based stroke study. Cerebrovasc Dis. 2011;31:419–26.
6. Wang D, Liu M, Hao Z, Tao W, Lin S, Zhang S, et al. Features of acute ischemic stroke with rheumatic heart disease in a hospitalized Chinese population. Stroke. 2012;43:2853–7.
7. Lamassa M, Di Carlo A, Pracucci G, Basile AM, Trefoloni G, Vanni P, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (the European community stroke project). Stroke. 2001;32:392–8.
8. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005;36:1115–9.
9. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (esc). Eur Heart J. 2010;31:2369–3429.
10. Steger C, Pratter A, Martinek-Bregel M, Avanzini M, Valentin A, Slany J, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian stroke registry. Eur Heart J. 2004;25:1734–40.
11. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;3:CD001927.
12. Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patientswith non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;3:CD006186.
13. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, et al. ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2011;123:104–23.
14. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/ American stroke association. Stroke. 2011;42:227–76.
15. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(638–645):e634.
16. Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: resultsof aWHO collaborative study. BullWorld Health Organ. 1980;58:113–30.
17. Wang D, Liu M, Hao Z, Tao W. Association between reduced kidney function and clinical outcomes after ischaemic stroke with atrial fibrillation. Eur J Neurol. 2014;21:160–6.
18. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864–70.
19. de Haan R, Limburg M, Bossuyt P, van der Meulen J, Aaronson N. The clinical meaning of rankin ’handicap’ grades after stroke. Stroke. 1995;26:2027–30.
20. Haeusler KG, Konieczny M, Endres M, Villringer A, Heuschmann PU. Impact of anticoagulation before stroke on stroke severity and long-term survival. Int J Stroke. 2012;7: 544–50.
21. Schwammenthal Y, Bornstein N, Schwammenthal E, Schwartz R, Goldbourt U, Tsabari R, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the national acute stroke israeli survey [nasis]). Am J Cardiol. 2010;105:411–6.
22. Johnsen SP, Svendsen ML, Hansen ML, Brandes A, Mehnert F, Husted SE. Preadmission oral anticoagulant treatment and clinical outcome among patients hospitalized with acute stroke and atrial fibrillation: a nationwide study. Stroke. 2014;45: 168–75.
23. Kwok CS, Skinner J, Metcalf AK, Potter JF, Myint PK. Prior antiplatelet or anticoagulant therapy and mortality in stroke. Heart. 2012;98:712–7.
24. O’Donnell M, Oczkowski W, Fang J, Kearon C, Silva J, Bradley C, et al. Preadmission antithrombotic treatment and stroke severity in patients with atrial fibrillation and acute ischaemic stroke: an observational study. Lancet Neurol. 2006;5:749–54.
25. Wang C, Yang Z, Wang Y, Zhao X, Liu L, Wang DZ, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry. J Stroke Cerebrovasc Dis. 2014;23(5):1157–63.
26. Lopes RD, Shah BR, Olson DM, Zhao X, Pan W, Bushnell CD, et al. Antithrombotic therapy use at discharge and 1 year in patients with atrial fibrillation and acute stroke: results from the avail registry. Stroke. 2011;42:3477–83.
27. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;4:CD000187.
28. Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2004;2:CD000185.
29. Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, et al. Simplified modified rankin scale questionnaire: reproducibility over the telephone and validation with quality of life. Stroke. 2011;42:2276–9.
30. Dennis M, Mead G, Doubal F, Graham C. Determining the modified rankin score after stroke by postal and telephone questionnaires. Stroke. 2012;43:851–3.